Delivery Order SPE2DB22D2206-SPE2DB25FHV99
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $17,483.59 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit packaging) on July 14, 2025, with completion targeted for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026. The order will be fulfilled...
- The Defense Logistics Agency awarded a $40,566.55 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $32,318.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for RINVOQ ER 15 mg tablets (30-unit bottles) under a firm fixed-price contract valued at $10,362.56. This is a non-set-aside competitive award with an ultimate completion date of July 30, 2025. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a $7,666.65 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with a completion date of July 30, 2025, and performance taking place at the contractor's Conshohocken, Pennsylvania location. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a $26,755.07 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 18, 2025, with completion expected by June 20, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside award issued under AmerisourceBergen's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $30,927.58 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This is a firm fixed-price, non-set-aside contract executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion global pharmaceutical support vehicle running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $26,154.99 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of RINVOQ ER 30 mg tablets (quantity: 30-unit bottles). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $13.3K delivery order to AmerisourceBergen Drug Corp on May 8, 2025, for RINVOQ ER 15 mg tablets (30-count units). This competitive, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for RINVOQ ER 15 MG tablets (UU 30s) with a ceiling value of $14,051.64. This firm fixed-price delivery order, which represents no set-aside designation, is part of AmerisourceBergen's broader indefinite delivery contract (IDC) with DLA Troop Support Medical valued at $999.99 billion through December 2026. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FHV99Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,859.53 to AmerisourceBergen Drug Corp on July 14, 2025, for RINVOQ ER 15 mg tablets (quantity: 30 units). This competitive award, using firm fixed price terms with no set-aside designation, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 15, 2025. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen Drug Corp supplies an extensive portfolio of pharmaceutical products and medical supplies to support military and veteran healthcare systems. The company maintains a significant $999,999,999 indefinite delivery vehicle with DLA Troop Support Medical through December 2026, which enables flexible procurement of specialty medications, brand-name and generic drugs, vaccines, and other medical commodities across multiple therapeutic domains. This particular delivery order for RINVOQ, a JAK inhibitor used in rheumatoid arthritis treatment, exemplifies the company's role in supporting Defense Health Agency and other federal healthcare system requirements on a competitive basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.9k | 7/14/25 |